Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence.
IV
RA
SC
TNF inhibitors
infliximab
intravenous
rheumatoid arthritis
subcutaneous
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
02
2022
accepted:
04
05
2022
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
The first subcutaneous (SC) formulation of infliximab CT-P13 has been authorized for the treatment of rheumatoid arthritis (RA) in Europe in 2019. Later, in 2020, approved indications were extended also to ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease (CD) and ulcerative colitis (UC). The present review provides summary of the key features of SC infliximab, with particular focus on pharmacokinetic profile, clinical development program in comparison with the intravenous (IV) formulation, and the latest evidence in the literature. We conclude that SC infliximab represents a new and promising approach in the treatment of patients with RA, offering an optimized clinical profile and a more practical option in comparison to the IV formulation. Nevertheless, SC formulation can improve the use of national health systems resources (e.g., through the time of healthcare workers not having to supervise infusions) and facilitate social distancing measures during the COVID-19 pandemic, as the patient can self-inject the medicine at home without going to the hospital. The limitations of the SC infliximab are mainly due to the limited experience of use in clinical practice and the absence of long-term drug retention data.
Identifiants
pubmed: 35673354
doi: 10.2147/JIR.S240593
pii: 240593
pmc: PMC9167594
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3259-3267Informations de copyright
© 2022 Iannone et al.
Déclaration de conflit d'intérêts
AF is an employee of Celltrion Healthcare Italy srl. Professor Fabrizio Conti reports personal fees from Lilly, personal fees from BMS, personal fees from Galapagos, personal fees from AbbVie, personal fees from Pfizer, outside the submitted work. Professor Roberto Caporali reports personal fees from pfizer, personal fees from AbbVie, personal fees from amgen, personal fees from celltrion, personal fees from BMS, personal fees from Lilly, personal fees from MSD, personal fees from Fresenius-Kabi, personal fees from Galapagos, during the conduct of the study. The other authors report no conflicts of interest in this work.
Références
Ann Rheum Dis. 2016 Jan;75(1):3-15
pubmed: 25969430
Ann Rheum Dis. 2005 May;64(5):704-7
pubmed: 15485995
Ther Drug Monit. 2010 Apr;32(2):232-6
pubmed: 20216124
Ann Rheum Dis. 2019 Nov;78(11):1463-1471
pubmed: 31511227
PLoS One. 2016 Nov 16;11(11):e0166443
pubmed: 27851772
Autoimmun Rev. 2021 Jul;20(7):102849
pubmed: 33974946
Sci Rep. 2021 Jul 23;11(1):15051
pubmed: 34302036
Rheumatology (Oxford). 2021 May 14;60(5):2277-2287
pubmed: 33230526
Biologics. 2009;3:183-91
pubmed: 19707407
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Nat Rev Dis Primers. 2018 Feb 08;4:18001
pubmed: 29417936
Arthritis Rheum. 2003 Jan;48(1):59-63
pubmed: 12528104
J Rheumatol. 2006 May;33(5):847-53
pubmed: 16583466
Arthritis Res Ther. 2021 Apr 16;23(1):119
pubmed: 33863352
Ann Intern Med. 2019 Jan 1;170(1):ITC1-ITC16
pubmed: 30596879
Frontline Gastroenterol. 2021 May 27;13(1):89-90
pubmed: 34966537
Clin Rheumatol. 2005 Apr;24(2):117-22
pubmed: 15340864
Int J Mol Sci. 2019 Sep 05;20(18):
pubmed: 31491879
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):88-89
pubmed: 33444534
Ann Rheum Dis. 2005 Jan;64(1):130-3
pubmed: 15608311
Mod Rheumatol. 2009;19(5):478-87
pubmed: 19626391
Expert Rev Clin Immunol. 2021 Jan;17(1):85-99
pubmed: 33305638